Literature DB >> 17260151

Methicillin resistant Staphylococcus aureus versus methicillin sensitive Staphylococcus aureus adult haematogenous septic arthritis.

Shafic S Al-Nammari1, Peter Bobak, Ramakrishnan Venkatesh.   

Abstract

INTRODUCTION: Septic arthritis is an orthopaedic emergency and Staphylococcus aureus (SA) is the number one cause. Methicillin resistant Staphylococcus aureus (MRSA) is increasing in incidence but how it differs from methicillin sensitive Staphylococcus aureus (MSSA) septic arthritis is unclear. Our aim was to delineate the differences in clinical features and outcomes between patients with MRSA and MSSA septic arthritis.
MATERIALS AND METHODS: We performed a retrospective review of all adult patients presenting to our institute over a 5 year period from June 2000 to June 2005 with haematogenous septic arthritis. We identified 15 cases of MRSA and 43 cases of MSSA septic arthritis. Fisher's exact test and the Student's t-test were used in analysis.
RESULTS: MRSA and MSSA predominantly affected males 60 versus 79%. MRSA cases were older with a mean age of 76 versus 44 years (P < 0.05), and had more comorbidities with a mean of 2.7 versus 1.35 (P < 0.05). In MRSA and MSSA cases the main sources of sepsis were unknown (20 vs. 47%), intravenous lines (47 vs. 2%), soft tissue infection (13 vs. 2%) and intravenous drug use (7 vs. 49%). MRSA was significantly more associated with intravenous line sepsis (P < 0.05), soft tissue infection (P = 0.05) and to be nosocomial (P < 0.05). MSSA was significantly more associated with IVDU (P < 0.05). Presentation was similar in both groups although MRSA patients were significantly more likely to be pyrexial (80 vs. 40%, P < 0.05) and to have glenohumeral involvement (P < 0.05) while MSSA was significantly more likely to affect the knee (P < 0.05). There were no significant differences between the total length of antimicrobial therapy in MRSA and MSSA patients (43 vs. 38 days, P > 0.2), or the number of surgical interventions required (1.8 vs. 1.6, P > 0.2). However MRSA patients were significantly more likely to be placed on inappropriate empirical antimicrobials pending sensitivities (93 vs. 0%, P < 0.05). Outcomes were similar in MRSA and MSSA patients with no significant differences in recurrences (0 vs. 10%, P > 0.2) or sepsis related mortality (13.3 vs. 6.9%, P > 0.2). MRSA, however, did show a strong towards a higher all cause 6 month mortality (26 vs. 7%, P = 0.07).
CONCLUSION: MRSA septic arthritis tends to affect older patients with multiple comorbidities and has a tropism for the glenohumeral joint while MSSA has a tropism for the knee. We did not find a significant difference in required length of antimicrobials, number or requirement of operative interventions or outcomes in terms of number of recurrences or sepsis related mortality. However MRSA septic arthritis patients were found to have a strong trend towards an increased all cause 6 month mortality and were significantly more likely to receive inappropriate empirical antimicrobials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260151     DOI: 10.1007/s00402-007-0285-z

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  14 in total

1.  Outcomes of revision total knee arthroplasty after methicillin-resistant Staphylococcus aureus infection.

Authors:  Dann J Laudermilch; Catherine J Fedorka; Alma Heyl; Nalini Rao; Richard L McGough
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

2.  Editorial: Do-Not-Resuscitate Orders and Advance Directives--Existential Issues for Orthopaedic Patients with Life-threatening Conditions.

Authors:  Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2016-01-14       Impact factor: 4.176

3.  Septic arthritis in the native joint.

Authors:  Meghan B Brennan; Jennifer L Hsu
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 4.  Clinical outcomes involving patients that develop septic arthritis with methicillin sensitive staphylococcus aureus versus methicillin resistant staphylococcus aureus.

Authors:  Kristen Combs; Kyle Cox
Journal:  J Orthop       Date:  2017-11-06

5.  Molecular and phenotypic characteristics of methicillin-resistant and vancomycin-intermediate staphylococcus aureus isolates from patients with septic arthritis.

Authors:  Wei-Yao Wang; Shih-Yi Lee; Tzong-Shi Chiueh; Jang-Jih Lu
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948

6.  Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.

Authors:  Anne Sandberg; Jonas H R Hessler; Robert L Skov; Jens Blom; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

7.  De novo methicillin-resistant Staphylococcus aureus vs. methicillin-sensitive Staphylococcus aureus infections of the spine, similar clinical outcome, despite more severe presentation in surgical patients.

Authors:  Basem Ishak; Amir Abdul-Jabbar; Gregory B Moss; Emre Yilmaz; Alexander von Glinski; Sven Frieler; Andreas W Unterberg; Ronan Blecher; Juan Altafulla; Jeffrey Roh; Robert A Hart; Rod J Oskouian; Jens R Chapman
Journal:  Neurosurg Rev       Date:  2020-08-27       Impact factor: 3.042

Review 8.  Novel therapeutic interventions towards improved management of septic arthritis.

Authors:  Jian Wang; Liucai Wang
Journal:  BMC Musculoskelet Disord       Date:  2021-06-09       Impact factor: 2.362

9.  High Prevalence of Methicillin-Resistant Staphylococcus aureus among Patients with Septic Arthritis Caused by Staphylococcus aureus.

Authors:  Wei-Ting Lin; Chung-Da Wu; Shun-Chien Cheng; Chong-Chi Chiu; Chi-Chou Tseng; Huan-Tee Chan; Po-Yih Chen; Chien-Ming Chao
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

10.  Comparison of clinical features and outcomes of staphylococcus aureus vertebral osteomyelitis caused by methicillin-resistant and methicillin-sensitive strains.

Authors:  Shinichi Inoue; Tokuhide Moriyama; Yutaka Horinouchi; Toshiya Tachibana; Fumiaki Okada; Keishi Maruo; Shinichi Yoshiya
Journal:  Springerplus       Date:  2013-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.